Clindamycin

C. diff Risk

High

Oral Bioavailability

Good (70 to 90%)

Approximate Cost

$0.45 (PO)
$5.28 (IV)

Dosing

Usual indications
300-450mg IV q8h

Necrotizing SSTI or toxic shock syndrome
900mg IV q8h

Oral Dosing
300-450mg PO q6-8h

No dosage adjustment required in renal dysfunction
</span>

No supplemental doses required for Intermittent HD patients

General Information

Common Usage

Anaerobic infections above the diaphragm, especially dental infection.

Gram positive skin and soft tissue infections including necrotizing fasciitis as an adjunctive agent to a beta lactam for reducing toxin production.

Skin & soft tissue infections involving susceptible MRSA.

Susceptible infections and surgical prophylaxis in setting of IgE mediated beta-lactam allergy.

For decreasing toxin production in toxic shock syndrome.

Drug Monitoring

None specific. Monitor for diarrhea.

Major Interactions

Muscle relaxants, e.g., atracurium, baclofen, diazepam.

St. Johns Wort

Tablet/Capsule Strengths

OPEN BENEFIT (PO)
No prescribing restrictions

Additional Information

IV Administration
Doses up to 900 mg: dilute in 100 mL D5W or NS and administer over 30 min.

EH Prescribing Restrictions
None

Community IV Formulary (Metro Area)
YES

Capsules can be opened and administered via NG route; Liquid formulation also available

Pharmacology

Antimicrobial class: Lincosamide

Pregnancy category: B

Average serum half life: 2.4 hours

Biliary penetration: Therapeutic

CSF penetration: Poor

Lung penetration: Therapeutic

Urine penetration: Poor